| Name | Title | Contact Details |
|---|---|---|
Michael Cola |
Chief Executive Officer | Profile |
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.
Leesville Rehabilitation Hospital is a Leesville, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ADS is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Boston Biochem is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RiboCor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.